Article
Adeno-Associated Virus Gene Therapy for Hemophilia
14 Sept 2022
Abstract excerpt
In vivo gene therapy is rapidly emerging as a new therapeutic paradigm for monogenic disorders. For almost three decades, hemophilia A (HA) and hemophilia B (HB) have served as model disorders for the development of gene therapy. This effort is soon to bear fruit with completed pivotal adeno-associated viral (AAV) vector gene addition trials reporting encouraging results and regulatory approval widely anticipated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
